Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by BlueMetal75on Aug 28, 2019 3:33pm
122 Views
Post# 30076193

RE:RE:RE:Number of shares.

RE:RE:RE:Number of shares.When it comes to an eventual buyout, I have always done my math at 200 million total shares. So now it will be 300 million. (With the tens of millions of dollars we now have in the bank and coming in the future due to already-issued warrants, there should be no need for any further dilution. Ever).

So if you assume a $10 billion buyout price, the jump in shares from 200 to 300 million bumps down our take from $50 per share to $33 a share.  And you know what, I can live with 33+ per share. I think I said previously I would sell my whole stash at $25 anyway.

Anyway, it's done. We are now fully cashed up; no more BionicJoke taunting us about how we can possibly pay for a Phase II trial. So let's move forward and get to it. It's been the "Summer of Pain" for us shareholders. Time to put that unpleasantness in the rear view mirror!

Good luck to all longs!
Bullboard Posts